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Barbara Gilchrest, in her inaugural Editorial for this series on translational research, related that her clinical experiences kin-
dled a desire to pursue laboratory-based training 
to bridge “basic discoveries at the cellular and 
molecular level with improvements in patient 
care” (Gilchrest, 2015). Her approach was bed-
side to the bench (...and back). My career had 
just the opposite genesis. I wanted principally to 
do fundamental biochemistry and cell biology 
and, indeed, embarked on a postdoctoral career 
studying tadpole metamorphosis under the tute-
lage of Arthur Eisen, then head of the Division of 
Dermatology at Washington University School 
of Medicine in St. Louis. That I found a career 
in dermatology, let alone one steeped richly in 
translational research, is due largely to consum-
mately practical advice from two people.
Before I delve into the rest of that story, I want 
to set the stage. When she invited me to write an 
Editorial, Dr. Gilchrest asked me to review my 
career and the insights that fostered movement 
from fundamental research to academic admin-
istration and finally to industry. Reflecting on 
this challenge, I quickly realized that the assign-
ment was not about my career, but rather about 
the plethora of challenges and opportunities that 
dermatology (writ large) offers to all of us. This 
commentary begins in the mid- to late 1960s, a 
scientifically fertile time for the deployment of 
nascent technologies, to bring them to bear on 
dermatologic diseases and to allow for observa-
tions that had theretofore been impossible.
Early in my postdoctoral career, one of the 
most stimulating descriptions of the scientif-
ic state of dermatology was offered in a 1967 
New England Journal of Medicine review by 
Irwin Freedberg, then at Harvard Medical 
School and later chairman of the Department 
of Dermatology at New York University School 
of Medicine. In his article, entitled “Rashes 
and Ribosomes,” Freedberg stated, “The era of 
the rash is in the past, and the era of complete 
understanding of dermatologic problems is still 
in the future” (Freedberg, 1967). Not given to 
unsubstantiated generalities, Freedberg cited as 
an example the importance of correlating recent 
electron microscopic insights with fundamen-
tal protein-synthetic and nucleic acid labeling 
studies to probe mechanisms of diseases such 
as psoriasis and ichthyosis. He reviewed the 
extant thinking about psoriasis to be the result 
of a process that “is genetically determined with 
a positive family history.” He went on to say 
that, without proof, “I am certain that [psoria-
sis] is related to an abnormality in the control of 
either epidermal cell division or differentiation” 
and that data “have pointed to the existence of 
substances in skin ... that will control epidermal 
proliferation.” His prescience joined that of per-
haps a dozen others in dermatology at the time 
to adumbrate subsequent decades of work that 
have elucidated the complex genetic underpin-
nings of psoriasis along with a mind-boggling 
array of cytokine interdependencies that are 
keys both to the pathogenesis of the disease 
and to our hopes for rational interventions. At 
the time, such examples represented for me the 
excitement of being part of a discipline under-
going a metamorphosis from the descriptive to 
the mechanistic.
While the 1960s saw the blossoming of der-
matologic clinical scientists deeply interested 
in the fundamental underpinnings of cutane-
ous biology, Freedberg (1967) used the “Rashes 
and Ribosomes” report to review how emerging 
techniques could also be used to understand 
therapy. He showed that when the widely used 
topical coal tar and UV light therapy (the so-
called Goeckerman regimen) produced clinical 
remission of psoriasis, there was a concomitant 
fivefold decrease in DNA and RNA synthesis, as 
well as a significant decrease in protein synthe-
sis, in the psoriatic plaques. Again, the excite-
ment for me was the articulation of a collective 
sentiment, among an impressive array of der-
matologic clinical scientists and skin biologists, 
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that we were working at the dawn of a mechanism-based 
approach to fuel dermatologic therapeutics.
From our enlightened vantage point more than four 
decades later, we acknowledge—both intuitively and explic-
itly—that discovery of fundamental pathways will lead to 
better therapeutics. But acknowledgment also embodies a 
challenge: how do we maintain the flow of basic knowledge 
and what is the best way to ensure its translation into thera-
peutics? Now, as in the mid-1960s, dermatology remains 
ripe for innovation. Indeed, various waves of innovation have 
occurred over the past 50 years, including systemic and topi-
cal steroids for control of cutaneous inflammatory disorders; 
antimetabolites and immunosuppressive agents for control of 
psoriasis; systemic and topical antibiotics for the treatment 
of acne; systemic and topical retinoids for use in disorders 
of keratinization and in acne; novel forms of phototherapy, 
such as psoralen plus UVA and later narrow-band UVB, for 
amelioration of psoriasis and mycosis fungoides; calcineurin 
inhibitors for control of eczema; and biologics for the treat-
ment of psoriasis. Each of these embodied the paradigm of 
bench to bedside to bench, as increasing efficacy and safety 
data impinged on product and/or regimen design. In a great-
er sense, as important as these advances have been to the 
lives of our patients, their emergence has been sporadic and 
stuttered at best.
My lifelong career conviction has been that maintenance 
of a flow of knowledge and discovery is crucial to survival, 
let alone a robust thriving, of dermatology. In 2000, I was 
deeply ensconced in issues related to payment for services 
in a major academic medical center. I argued that, despite 
the fact that—from an intellectual standpoint—dermatology 
had never been more exciting, much of the public and many 
payer organizations considered dermatology the study of rela-
tively trivial diseases requiring little expertise and deserving 
minimal investment (Bauer, 2000). I further argued that pub-
lic perception of dermatologists as aestheticians reinforced 
the very trivialization that we wished to avoid. In the inter-
vening almost 15 years, little has changed to alter those per-
ceptions. Let me emphasize that I in no way denigrate the 
need for dermatology and dermatologists to be responsive to 
the quality-of-life issues driven by patients’ deep self-image 
needs. Rather, I argue that our value must rest on a solid sci-
entific foundation and that we must, with one voice, articu-
late how science informs the needs—medical, surgical, and 
aesthetic—of patients.
Let me now return to advice given me by two wise men-
tors, both of whom counseled—not only with words but also 
by example. The first was Ruth Freinkel, who at the time was 
professor of dermatology at Northwestern University School 
of Medicine. As a medical student, I sought Ruth’s advice 
about where to begin my laboratory research career. She 
could have urged me to stay at Northwestern, but with great 
generosity of spirit Ruth suggested that I go the Eisen lab at 
Washington University in St. Louis. The basis for her advice 
rested with the excellence of the science being done by Eisen 
and his collaborators, although I believe her more subtle goal 
was to ensure that I would be compelled by the excitement of 
doing real science as it related to dermatology. In retrospect, 
she could not have been more right, because the second role 
model was Arthur Eisen himself. What I learned from Arthur 
was multifold:
• To recognize the importance of the unity of science 
(i.e., genetic principles, protein-synthetic mechanisms, 
and regulatory controls transcend species and are, in 
principle, the same in bacteria, in amphibians, and in 
humans)
• To allow trainees to follow their noses scientifically and to 
provide a nurturing environment not excessively fettered 
by superfluous structure
• To encourage broad thinking and appreciation that the 
applicability of a technique used in a different discipline 
might apply to dermatology and that curiosity, tenacity, 
and common sense can pay off
• To develop a trusted team of basic and clinical scientists 
to engender cross-fertilization for optimal movement of 
projects—both basic and clinical—to fruition
These same principles have continued to guide me in my 
stints as department chairman, dean, and entrepreneur.
Perhaps the best example of a transition from funda-
mental research to industry is that of my first encounters 
with Genentech. During my Washington University tenure, 
our fundamental research involved connective tissue biol-
ogy and biochemistry—synthesis and degradation of col-
lagen—in health and disease. Inevitably, this led us (Jouni 
Uitto, then at Washington University, now chairman of der-
matology at Jefferson Medical College, and me) to an inter-
est in scleroderma and an examination of collagen-synthetic 
and matrix metalloproteinase expression in scleroderma 
fibroblasts. Our patient-oriented research was not truly 
translational; rather, it employed patient-derived cells to 
probe mechanisms (Uitto et al., 1979). Upon my arrival at 
Stanford, Edward Amento, who at the time headed a con-
nective-tissue/immunology group at Genentech, asked me 
to consider using recombinant human relaxin, an inducer of 
expression of matrix metalloproteinase I, as a possible ther-
apy for scleroderma. We filed an investigator-initiated inves-
tigational new drug application with the US Food and Drug 
Administration (FDA) and treated one patient who suffered 
from moderately severe systemic sclerosis. The results were 
sufficiently encouraging to allow us (Amento at Genentech; 
Brian Seed, professor of genetics at Harvard Medical School; 
and me) to outlicense the relaxin technology and form our 
first company, at the time known as Connective Therapeutics 
and later renamed Connetics Corporation. We had come at 
least half-circle from bench to bedside. What we learned 
from later scleroderma patients would take us full-circle, 
i.e., from the bedside back to the bench. We learned that 
the amelioration of tissue fibrosis was seen in only some 
patients, and even in them it was not durable. The lesson was 
an important one—not to have tried would have guaranteed 
failure. To have tried for a solid-cell biologic/biochemical 
rationale at least informed future therapeutic avenues. Sadly, 
scleroderma remains one of the greatest challenges of der-
matologists and rheumatologists.
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Generally, however, there remains great cause for hope 
and enthusiasm. Dermatology, as a clinical-scientific disci-
pline, has been a leader in elucidating genotype–phenotype 
correlations. The reason is obvious: we can, literally, see the 
phenotype. The addition of the powerful tools of the genomic 
revolution offers the basis for understanding hereditary dis-
eases of the skin, such as epidermolysis bullosa (Fine et al., 
2014), and further offer the promise of not only symptomatic 
but also corrective therapy (Woodley et al., 2013; Cogan et 
al., 2014; Siprashvili et al., 2010; Sun et al., 2014). Novelty 
continues to drive the industry side of dermatologic thera-
peutics as well, with the founding of several new companies, 
including our own, palpably focused on innovation.
Let me extend the analogy: to the same degree that we 
can see the problems of skin diseases, there is also an elegant 
simplicity in being able to see and measure the responses 
to therapy. Admittedly to oversimplify, the regulatory path-
way for approval of dermatologic therapies is predictable 
and straightforward. As a generality, both efficacy and safety 
observations made in an adequately powered proof-of-con-
cept trial have a reasonable probability of being sustained in 
later stages of development. Unlike many trials for therapeu-
tics in internal medicine, we are not generally burdened with 
measuring an evanescent surrogate marker before we assess 
efficacy in the “real” disease. Rather, with the approbation of 
the FDA, we as dermatologists rely largely on three impor-
tant parameters: an absolute change in number (or size) of 
lesions, a physician–investigator global assessment of change 
(improvement), and, increasingly, a patient-reported out-
come instrument.
If our ultimate goal is to improve the lives of our patients, 
let me posit that there is not one perfect way to success. I 
do believe, however, that there are more, and less, efficient 
ways to bring fundamental insights to improved patient care. 
In a Commentary for this journal in 2012, David Cohen, 
professor of dermatology at New York University School of 
Medicine, and I discussed the changing roles of industry 
and academia. We observed that ancient silos are breaking 
down, that both industry and academic and research institu-
tions are engaging in basic research and applications, and 
that there is an essential porosity between bench and bed-
side (Bauer and Cohen, 2012). However, the fact that such 
barriers are being eroded does not a priori mean that the 
blurring of functions will lead to the most efficient pathway 
for development of a new therapeutic. Several academic 
institutions are now initiating programs, not only to cap-
ture intellectual property but also to invest in early-stage 
development. During my tenure as dean, I, too, argued for 
such an approach, which subsequently was implemented 
at Stanford, albeit on a small scale. One advantage of this 
approach is that the physician–scientists who discover a pos-
sible therapy will often be the very ones to whom patients 
are referred. With appropriate oversight, they should indeed 
have an opportunity to engage in early-stage, proof-of-con-
cept trials. However, having been in industry for the past 14 
years as cofounder of two companies and as founding CEO 
of a third, I now have a somewhat more robust perspective, 
one first articulated to me by Paul Berg, Nobel Laureate and 
professor of biochemistry at Stanford University School of 
Medicine. Paul’s deep conviction is that the essential role 
of universities and research institutions is discovery, and the 
role of industry is application and development to commer-
cialization. To follow this paradigm draws on the inherent 
strengths of each, ensures that scientific creativity will not be 
sidetracked by a focus on application, and places later clini-
cal development (i.e., beyond proof of concept) in the hands 
of those who are best equipped to oversee the nuances of 
regulatory pathways and all the preclinical, pharmaceutical 
sciences, and manufacturing requirements.
As dermatologists, we exist in a specialty where we have 
a deep connection to our patients. We must be especially 
attentive on a daily basis to both the visual (i.e., the medical/
surgical) and the psychosocial (i.e., the emotional) aspects of 
our patients’ diseases. We should be opportunistic and accept 
clinical challenges to think about, create, and participate in 
patient-oriented research. As Ruth Freinkel said in an inter-
view published posthumously (Paller and Bauer, 2014), “If 
anyone is interested in research of the skin, it will be hard. But 
if you do it successfully, there’s nothing equal to the feeling of 
having accomplished something that is really important.”
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